Positive News Sentiment NASDAQ:VBIV VBI Vaccines - VBIV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.30 +0.01 (+5.15%) (As of 03/27/2023 05:26 PM ET) Add Compare Share Share Today's Range$0.28▼$0.3150-Day Range$0.29▼$0.6452-Week Range$0.24▼$1.86Volume867,464 shsAverage Volume896,686 shsMarket Capitalization$77.58 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability VBI Vaccines MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside565.8% Upside$2.00 Price TargetShort InterestBearish6.18% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.28) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector801st out of 995 stocksPharmaceutical Preparations Industry390th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingVBI Vaccines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, VBI Vaccines has a forecasted upside of 565.8% from its current price of $0.30.Amount of Analyst CoverageVBI Vaccines has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.18% of the float of VBI Vaccines has been sold short.Short Interest Ratio / Days to CoverVBI Vaccines has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.Change versus previous monthShort interest in VBI Vaccines has recently increased by 8.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVBI Vaccines does not currently pay a dividend.Dividend GrowthVBI Vaccines does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVBI Vaccines has received a 51.81% net impact score from Upright. VBI Vaccines seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for VBI Vaccines is -0.75. Previous Next 2.7 News and Social Media Coverage News SentimentVBI Vaccines has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for VBI Vaccines this week, compared to 1 article on an average week.Search InterestOnly 17 people have searched for VBIV on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added VBI Vaccines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VBI Vaccines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of VBI Vaccines is held by insiders.Percentage Held by InstitutionsOnly 38.24% of the stock of VBI Vaccines is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VBI Vaccines are expected to grow in the coming year, from ($0.28) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VBI Vaccines is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VBI Vaccines is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVBI Vaccines has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About VBI Vaccines (NASDAQ:VBIV) StockVBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.Read More Receive VBIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address VBIV Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comAnalysts Offer Predictions for VBI Vaccines Inc.'s Q4 2023 Earnings (NASDAQ:VBIV)March 17, 2023 | americanbankingnews.comVBI Vaccines Inc. (NASDAQ:VBIV) Expected to Earn Q1 2023 Earnings of ($0.07) Per ShareMarch 27, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 15, 2023 | msn.comVBI Vaccines Earnings Perspective: Return On Capital EmployedMarch 15, 2023 | finance.yahoo.comVBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 13, 2023 | finance.yahoo.comVBI Vaccines Reports Full Year 2022 Financial ResultsFebruary 24, 2023 | usatoday.comMpox vaccine worked well, safely, CDC data shows. Committee votes to continue its use.February 24, 2023 | abcnews.go.comFlu vaccine worked well in season that faded fast, CDC saysMarch 27, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!February 24, 2023 | cnn.comCDC advisers vote in favor of using mpox vaccine in future outbreaksFebruary 24, 2023 | nypost.comFirst-ever RSV vaccine could be approved, roll out by AugustFebruary 23, 2023 | finance.yahoo.comVBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside ChatFebruary 21, 2023 | forbes.comFirst FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their EffectivenessFebruary 20, 2023 | usnews.comModerna Bows to Pressure, Says COVID-19 Vaccines Will Remain Free After Emergency EndsFebruary 15, 2023 | finance.yahoo.comVBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis BJanuary 24, 2023 | finance.yahoo.comIndividual investors account for 55% of VBI Vaccines Inc.'s (NASDAQ:VBIV) ownership, while private equity firms account for 25%January 23, 2023 | nypost.comCOVID vaccine may make Botox less effective: studyJanuary 16, 2023 | abcnews.go.comCompanies look at increasing price of their COVID-19 vaccines. Bernie Sanders is not happyJanuary 12, 2023 | cnet.comFirst Ever Honeybee Vaccine Approved to Target Deadly Global DiseaseJanuary 12, 2023 | nbcnews.comA fake tweet spurred an anti-vaccine harassment campaign against a doctorJanuary 3, 2023 | usatoday.comFact check: Post falsely claims that FDA said Pfizer vaccines cause blood clotsDecember 17, 2022 | seekingalpha.comVBIV VBI Vaccines Inc.December 8, 2022 | finance.yahoo.comVBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in AdultsDecember 6, 2022 | finance.yahoo.comCEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines DealNovember 22, 2022 | finance.yahoo.comVBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual MeetingNovember 11, 2022 | finance.yahoo.comVBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual MeetingNovember 4, 2022 | finance.yahoo.comAdaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VBIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address VBIV Company Calendar Last Earnings3/13/2023Today3/27/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBIV CUSIPN/A CIK764195 Webwww.vbivaccines.com Phone(617) 830-3031FaxN/AEmployees149Year Founded2001Price Target and Rating Average Stock Price Forecast$2.00 High Stock Price Forecast$2.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+565.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,300,000.00 Net Margins-10,471.63% Pretax Margin-10,471.63% Return on Equity-115.47% Return on Assets-63.81% Debt Debt-to-Equity Ratio0.76 Current Ratio2.10 Quick Ratio1.92 Sales & Book Value Annual Sales$1.08 million Price / Sales71.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book1.20Miscellaneous Outstanding Shares258,260,000Free Float233,723,000Market Cap$77.58 million OptionableOptionable Beta1.92 Social Links Key ExecutivesJeff BaxterPresident, Chief Executive Officer & DirectorChristopher McNultyCFO, Director & Head-Business DevelopmentFrancisco Diaz-MitomaChief Medical OfficerDavid Evander AndersonChief Scientific OfficerT. Adam BuckleySenior Vice President-Business DevelopmentKey CompetitorsXilio TherapeuticsNASDAQ:XLOFortress BiotechNASDAQ:FBIOReviva PharmaceuticalsNASDAQ:RVPHCelularityNASDAQ:CELUvTv TherapeuticsNASDAQ:VTVTView All CompetitorsInstitutional OwnershipVoya Investment Management LLCBought 21,824 shares on 2/28/2023Ownership: 0.037%Captrust Financial AdvisorsSold 57,712 shares on 2/15/2023Ownership: 0.211%Millennium Management LLCSold 730,224 shares on 2/15/2023Ownership: 0.151%Jane Street Group LLCBought 177,354 shares on 2/15/2023Ownership: 0.104%Price T Rowe Associates Inc. MDSold 51,400 shares on 2/14/2023Ownership: 0.070%View All Institutional Transactions VBIV Stock - Frequently Asked Questions Should I buy or sell VBI Vaccines stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VBIV shares. View VBIV analyst ratings or view top-rated stocks. What is VBI Vaccines' stock price forecast for 2023? 1 analysts have issued 12-month price objectives for VBI Vaccines' stock. Their VBIV share price forecasts range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 565.8% from the stock's current price. View analysts price targets for VBIV or view top-rated stocks among Wall Street analysts. How have VBIV shares performed in 2023? VBI Vaccines' stock was trading at $0.3911 at the beginning of the year. Since then, VBIV shares have decreased by 23.2% and is now trading at $0.3004. View the best growth stocks for 2023 here. When is VBI Vaccines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our VBIV earnings forecast. How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc. (NASDAQ:VBIV) posted its quarterly earnings results on Monday, March, 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. The biopharmaceutical company earned $0.29 million during the quarter, compared to analysts' expectations of $1.98 million. VBI Vaccines had a negative trailing twelve-month return on equity of 115.47% and a negative net margin of 10,471.63%. What ETF holds VBI Vaccines' stock ? ETFMG Treatments Testing and Advancements ETF holds 56,036 shares of VBIV stock, representing 0.12% of its portfolio. What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie (). What is VBI Vaccines' stock symbol? VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV." Who are VBI Vaccines' major shareholders? VBI Vaccines' stock is owned by a number of retail and institutional investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (1.29%), Charles Schwab Investment Management Inc. (0.57%), Renaissance Technologies LLC (0.27%), Captrust Financial Advisors (0.21%), Millennium Management LLC (0.15%) and Deutsche Bank AG (0.11%). Insiders that own company stock include Life Sciences Maste Perceptive, Nell Beattie and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of VBI Vaccines? Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is VBI Vaccines' stock price today? One share of VBIV stock can currently be purchased for approximately $0.30. How much money does VBI Vaccines make? VBI Vaccines (NASDAQ:VBIV) has a market capitalization of $77.58 million and generates $1.08 million in revenue each year. The biopharmaceutical company earns $-113,300,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. How many employees does VBI Vaccines have? The company employs 149 workers across the globe. How can I contact VBI Vaccines? VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The official website for the company is www.vbivaccines.com. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at ir@vbivaccines.com. This page (NASDAQ:VBIV) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.